Evaluation of the Functional Status of Jejunoplasty and Coloplasty and Its Impact on Quality of Life (CEREC)

Sponsor
Hospital Universitari de Bellvitge (Other)
Overall Status
Recruiting
CT.gov ID
NCT05802459
Collaborator
(none)
36
1
56.5
0.6

Study Details

Study Description

Brief Summary

The goal of this prospective population-based cohort study is to assess:
  • The evolution of the functional status of patients undergoing complex esophageal reconstruction

  • Its impact on quality of life, depending on the type of conduit performed.

Participants

  • Will be asked to complete different quality of life questionnaires during every follow-up visit

  • Will undergo additional tests to assess functionality

Condition or Disease Intervention/Treatment Phase
  • Other: EORTC QLQ-C30
  • Other: EORTC QLQ-OG25
  • Other: GIQLI
  • Other: SWAL QoL
  • Procedure: Videofluoroscopy

Detailed Description

-General Justification: In recent years, esophageal reconstruction has been a great surgical challenge for the multidisciplinary teams in charge of carrying out this complex technique, associated with high morbidity and a high impact on the quality of life and functional status of patients.

One of the most important aspects of this surgery is the type of conduit used to restore digestive transit. Classically, gastroplasty has been the technique of choice due to its lower morbidity and mortality and less surgical complexity. On the other hand, in those patients in whom the stomach is not available, a coloplasty or a jejunoplasty is chosen, both of which can be associated with supercharged techniques to improve and ensure good vascular flow.

Currently, there is controversy about which type of conduit to use in the absence of a viable stomach. Since the introduction of microvascular or supercharged techniques, the postoperative results of jejunal grafts are comparable to coloplasty and even gastroplasty according to some authors.

The present study is an initiative of the Complex Esophageal Reconstruction Unit (UREC) of Bellvitge University Hospital (HUB), which aims to compare the different types of conduit used in complex esophageal reconstruction, assessing, in the short and long term, the postoperative functional status and its impact on quality of life through validated test-type tools, as well as carrying out complementary tests that allow evaluating aspects such as swallowing and dysphagia, among others.

  • Hypothesis Considering the results of quality of life and functionality in the short and long term, jejunoplasty (free, pedunculated ± supercharged) could be the second technique of choice to perform in the absence of gastric conduit in complex esophageal reconstruction.

  • Primary objective:

  1. To determine the differences in the quality of life of patients undergoing complex esophageal reconstruction by jejunoplasty (free, pedunculated ± supercharged) or coloplasty (± supercharged).

  2. To describe the functional evolution of complex esophageal reconstruction by jejunoplasty (free, pedunculated ± supercharged) or coloplasty (± supercharged).

  • Study design CEREC-2022 is a prospective population-based cohort study that aims to assess the evolution of the functional status of patients undergoing complex esophageal reconstruction and its impact on quality of life, depending on the type of conduit performed.

  • Study population The target population of this study is made up of patients who are candidates for complex esophageal reconstruction performed by the Complex Esophageal Reconstruction Functional Unit of the Bellvitge University Hospital (UREC-HUB), during the study period. All patients who are candidates for complete replacement of the esophagus through reconstruction are presented to the Committee of the Complex Esophageal Reconstruction Functional Unit of the Bellvitge University Hospital (UREC-HUB). After the multidisciplinary assessment, the most appropriate type of surgery for each patient is proposed and the patient receives the information during a scheduled appointment, at this moment the patient is asked to participate in the CEREC-2022 study.

  • Main Outcome

  1. Quality of life related to the swallowing function based on the conduit: it will be assessed using the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ C30), European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Oesophago Gastric module 25 (EORTC QLQ OG25), Gastrointestinal quality of life index (GIQLI) and Swallowing quality of life questionnaire (SWAL QoL)

  2. Number (percentage) of patients who present tolerance to the oral intake and need (volume in milliliters) of enteral nutrition depending on the type of conduit.

  • Secondary outcome Incidence of dysphagia evaluated by Videofluoroscopy (VDF), Incidence of stenosis of the conduit in the Upper Digestive Endoscopy (UDE), Number (percentage) of dilatations of the conduit, Number (percentage) of patients with esophagitis according to the Los Angeles classification, Nutritional status, Number (percentage) of specific complications of the surgery during admission according to the Esophageal Complication Consensus Group, Number of hospitalizations.

  • As this is an observational study of a low-prevalent surgical indication, it is expected to include all patients scheduled for surgery from September 2022 to September 2025.

  • The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
36 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Evaluation of the Functional Status of Jejunoplasty and Coloplasty in Patients Undergoing Complex Esophageal Reconstruction and Its Impact on Quality of Life (CEREC)
Actual Study Start Date :
Dec 15, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Patients undergoing complex esophageal reconstruction

All the patients who are candidates for complex esophageal reconstruction performed by the Complex Esophageal Reconstruction Functional Unit of the Bellvitge University Hospital (UREC-HUB), during the study period.

Other: EORTC QLQ-C30
central generic questionnaire associated with different disease specific modules

Other: EORTC QLQ-OG25
module to assess the quality of life in patients with esophagogastric disease.

Other: GIQLI
Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.

Other: SWAL QoL
Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.

Procedure: Videofluoroscopy
It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.

Outcome Measures

Primary Outcome Measures

  1. Quality of life related to the swallowing function assessed using the EORTC QLQ OG25, EORTC QLQ C30, GIQLI and SWAL QoL questionnaire. [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    This study aims to determine the differences in the quality of life of patients undergoing complex esophageal reconstruction by jejunoplasty (free, pedunculated ± supercharged) or coloplasty (± supercharged) using the following questionnaires: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ C30): All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Oesophago Gastric module 25 (EORTC QLQ OG25): All of the scales and single-item measures range in score from 0 to 100. A high score for all the scales and single-items represents a high level of symptomatology or problems. Gastrointestinal quality of life index (GIQLI): scale range from 0-144 Swallowing quality of life questionnaire (SWAL QoL): scale range from 0-100

  2. Number (percentage) of patients who present tolerance to the oral intake and need (volume in milliliters) of enteral nutrition depending on the type of conduit. [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    This study aims to describe the functional evolution of complex esophageal reconstruction by jejunoplasty (free, pedunculated ± supercharged) or coloplasty (± supercharged).

Secondary Outcome Measures

  1. Incidence of dysphagia [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Incidence of dysphagia evaluated by Videofluoroscopic (VDF) using the following scales: Videofluoroscopic dysphagia scale (VDS) Dysphagia outcome and severity scale(DOSS) Penetration-aspiration scale(PAS)

  2. Incidence of stenosis of the conduit [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Incidence of stenosis of the conduit in the Upper Digestive Endoscopy (UDE) that requires some therapeutic maneuver (dilatation), which is carried out during the follow-up visits: one year, two and three years.

  3. Number (percentage) of dilatations of the conduit [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number (percentage) of dilatations of the conduit, per patient, carried out during the UDE within the follow-up visits: one year, two and three years.

  4. Number (percentage) of patients with esophagitis [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number (percentage) of patients with esophagitis according to the Los Angeles classification evidenced in any of the UDE performed during the follow-up visits: one year, two and three years.

  5. Number (percentage) of patients with chronic diarrhea [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number (percentage) of patients with chronic diarrhea during follow-up

  6. Body Mass Index [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Weight and height will be combined to report Body Mass Index (BMI kg/m2) as a measure for indicating nutritional status

  7. Muscle strength measured by Handgrip strength (HGS) dynamometer [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Handgrip strength expressed in Kg and assessed using the reference values for age and sex

  8. Serum albumin value [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Measure of albumin/prealbumin in blood tests for assessment of nutritional status. Normal value: 34 - 54 g/L

  9. Mean 'time of need for enteral nutrition and oral nutrition supplements' [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Mean 'time of need for enteral nutrition and oral nutrition supplements' during the post-surgical follow-up period.

  10. Volume of enteral nutrition required [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Volume of enteral nutrition required during the post-surgical follow-up period.

  11. Number of hospitalizations [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number of hospitalizations, for any reason, during the post-surgical follow-up period.

  12. Number (percentage) of specific complications of the surgery during admission according to the Esophageal Complication Consensus Group (ECCG) [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number (percentage) of specific complications of the surgery during admission according to the Esophageal Complication Consensus Group (ECCG) (20), highlighting anastomotic dehiscence, surgical site infection, bleeding, need for reintervention, ischaemia of the graft (up to 90 ±3 days after surgery). Number (percentage) of complications according to the Clavien-Dindo classification (21) and Comprehensive Complication Index.

  13. Mortality [The follow-up of each patient included in the study will end 3 years after the intervention when the End of Study visit will be carried out.]

    Number (percentage) of deaths related to esophageal reconstruction (Up to 90 ±3 days after surgery).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients (≥ 18 years of age) and of both gender.

  • Candidates for complete esophageal reconstruction with cervical anastomosis, regardless of the etiology of the esophagectomy.

  • Decision to indicate a coloplasty (+/- supercharged) or jejunoplasty (free, pedunculated +/- supercharged) as surgical technique after evaluation by the UREC Committee.

  • Acceptance to participate in the study and comply with the program of procedures (schedule of visits).

  • Signing of the informed consent.

Exclusion Criteria:
  • Patients who withdraw their informed consent at any time during the course of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Uversitari de Bellvitge Barcelona Spain 08907

Sponsors and Collaborators

  • Hospital Universitari de Bellvitge

Investigators

  • Study Director: Leandre Farran, Bellvitge University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mònica Miró Martín, Associate surgeon and specialist in Upper Gastrointestinal surgery. PhD, MD., Hospital Universitari de Bellvitge
ClinicalTrials.gov Identifier:
NCT05802459
Other Study ID Numbers:
  • CEREC-2022
First Posted:
Apr 6, 2023
Last Update Posted:
Apr 6, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mònica Miró Martín, Associate surgeon and specialist in Upper Gastrointestinal surgery. PhD, MD., Hospital Universitari de Bellvitge
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2023